4,086 Shares in Haemonetics Co. (NYSE:HAE) Purchased by Empowered Funds LLC

Empowered Funds LLC purchased a new stake in shares of Haemonetics Co. (NYSE:HAE) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,086 shares of the medical instruments supplier’s stock, valued at approximately $319,000.

Other large investors also recently made changes to their positions in the company. Global Alpha Capital Management Ltd. bought a new stake in shares of Haemonetics in the 3rd quarter valued at approximately $806,000. Loomis Sayles & Co. L P increased its holdings in Haemonetics by 8.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier’s stock valued at $13,171,000 after buying an additional 12,310 shares during the period. BNP Paribas Financial Markets lifted its stake in Haemonetics by 174.5% during the third quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 10,774 shares during the period. Westfield Capital Management Co. LP raised its stake in Haemonetics by 10.9% during the third quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock worth $66,206,000 after acquiring an additional 80,783 shares in the last quarter. Finally, Boston Trust Walden Corp grew its stake in Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after buying an additional 106,114 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Down 0.5 %

HAE stock opened at $63.36 on Friday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The company’s 50-day simple moving average is $72.98 and its 200 day simple moving average is $76.76. The company has a market capitalization of $3.18 billion, a PE ratio of 24.95, a price-to-earnings-growth ratio of 1.12 and a beta of 0.39.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, sell-side analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current year.

Analysts Set New Price Targets

HAE has been the topic of a number of research reports. StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Needham & Company LLC cut their price objective on Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research note on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target on the stock. Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Finally, JMP Securities cut their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $101.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.